Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

JAZZ PHARMACEUTICALS PLC

(JAZZ)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Jazz Pharmaceuticals : UBS Adjusts Jazz Pharmaceuticals' Price Target to $234 From $236, Citing Revised Guidance; Buy Rating Kept

06/18/2021 | 10:24am EDT


ę MT Newswires 2021
All news about JAZZ PHARMACEUTICALS PLC
07/23JAZZ PHARMACEUTICALS : RBC Boosts Price Target on Jazz Pharmaceuticals to $216 F..
MT
07/23JAZZ PHARMACEUTICALS : Rylaze Added to National Comprehensive Cancer Network Gui..
MT
07/22Jazz Pharmaceuticals plc Announces National Comprehensive Cancer Network Adds..
CI
07/22PAO GROUP, INC. INTENDS GET ITS FIRS : Paog)
AQ
07/22LIGAND PHARMACEUTICALS INCORPORATED : Partner jazz pharmaceuticals launches ryla..
AQ
07/21LIGAND PHARMACEUTICALS INCORPORATED : Pharma to Receive $7 Million in Milestone ..
MT
07/21Ligand Partner Jazz Pharmaceuticals Launches RYLAZEÖ (asparaginase erwinia ch..
CI
07/20JAZZ PHARMACEUTICALS : Rylaze Investor Update
PU
07/20JAZZ PHARMACEUTICALS : to Report 2021 Second Quarter Financial Results on August..
PR
07/19JAZZ PHARMACEUTICALS : Financial Statements and Exhibits (form 8-K/A)
AQ
More news
Financials (USD)
Sales 2021 3 106 M - -
Net income 2021 -172 M - -
Net Debt 2021 5 461 M - -
P/E ratio 2021 -55,4x
Yield 2021 -
Capitalization 10 565 M 10 565 M -
EV / Sales 2021 5,16x
EV / Sales 2022 3,97x
Nbr of Employees 1 940
Free-Float 97,5%
Chart JAZZ PHARMACEUTICALS PLC
Duration : Period :
Jazz Pharmaceuticals plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends JAZZ PHARMACEUTICALS PLC
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 17
Last Close Price 173,26 $
Average target price 210,35 $
Spread / Average Target 21,4%
EPS Revisions
Managers and Directors
Bruce C. Cozadd Chairman & Chief Executive Officer
Daniel N. Swisher President
RenÚe D. Galß Chief Financial Officer & Executive Vice President
Robert Iannone Chief Medical Officer, EVP-Research & Development
Finbar Larkin Senior Vice President-Technical Operations
Sector and Competitors
1st jan.Capi. (M$)
JAZZ PHARMACEUTICALS PLC4.97%10 575
JOHNSON & JOHNSON9.21%452 602
ROCHE HOLDING AG11.50%327 852
PFIZER, INC.13.58%234 040
NOVARTIS AG-0.17%221 954
ELI LILLY AND COMPANY44.05%221 084